Roche's RoACTEMRA receives EU approval for use in patients with early rheumatoid arthritis (RA)

Roche announced today that RoACTEMRA (tocilizumab) has received approval from the European Commission for use in patients with severe, active and progressive RA who previously have not been treated with methotrexate (MTX). Treating the disease at this critical early phase may prevent irreversible damage to joints and long-term disability. RoACTEMRA is the first interleukin-6 (IL-6) receptor antagonist to be approved for use in Europe in patients with early RA.
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news